Robert Kirken to Drug Screening Assays, Antitumor
This is a "connection" page, showing publications Robert Kirken has written about Drug Screening Assays, Antitumor.
Connection Strength
0.085
-
Gutierrez DA, Contreras L, Villanueva PJ, Borrego EA, Mor?n-Santiba?ez K, Hess JD, DeJesus R, Larragoity M, Betancourt AP, Mohl JE, Robles-Escajeda E, Begum K, Roy S, Kirken RA, Varela-Ramirez A, Aguilera RJ. Identification of a Potent Cytotoxic Pyrazole with Anti-Breast Cancer Activity That Alters Multiple Pathways. Cells. 2022 01 12; 11(2).
Score: 0.050
-
Parra K, Valenzuela P, Lerma N, Gallegos A, Reza LC, Rodriguez G, Emmenegger U, Di Desidero T, Bocci G, Felder MS, Manciu M, Kirken RA, Francia G. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. Br J Cancer. 2017 01; 116(3):324-334.
Score: 0.035